Epidemiologic and economic effect of methicillin-resistant staphylococcus aureus in obstetrics

Richard H. Beigi, Katherine Bunge, Yeohan Song, Bruce Lee

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To quantify the epidemiologic and economic burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in the obstetric population, identify main factors influencing the magnitude of disease, and evaluate the cost-effectiveness of MRSA screening and decolonization. METHODS: A cost-effectiveness decision analytic model was constructed for estimations from both the societal and third party-payer perspectives. Probabilities were derived from prior studies when available. Cost data came from the Healthcare Cost and Utilization Project, medication wholesale prices, and the Centers for Medicare & Medicaid Services. Sensitivity analysis was conducted to assess the effect of variables across a range of values. RESULTS: Approximately 14,294 pregnant or postpartum women experience an invasive MRSA infection in the United States annually. The majority of invasive MRSA infections are mastitis (n=8,880). The annual economic effect of MRSA infections is projected to be approximately $8.7 million and approximately $8.0 million from the societal and payer perspectives, respectively. Sensitivity analyses demonstrate that the prevalence of MRSA, incidence of mastitis, and rate of cesarean deliveries were key driving factors for the estimations. CONCLUSION: Methicillin-resistant S aureus is an important emerging pathogen responsible for a modest burden of puerperal infections and associated costs. Universal screening and decolonization efforts do not currently seem to be cost-effective.

Original languageEnglish (US)
Pages (from-to)983-991
Number of pages9
JournalObstetrics and Gynecology
Volume113
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Obstetrics
Economics
Mastitis
Infection
Costs and Cost Analysis
Cost-Benefit Analysis
Puerperal Infection
Health Insurance Reimbursement
Methicillin Resistance
Cost of Illness
Medicaid
Medicare
Health Care Costs
Postpartum Period
Pregnant Women
Incidence
Population

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Epidemiologic and economic effect of methicillin-resistant staphylococcus aureus in obstetrics. / Beigi, Richard H.; Bunge, Katherine; Song, Yeohan; Lee, Bruce.

In: Obstetrics and Gynecology, Vol. 113, No. 5, 05.2009, p. 983-991.

Research output: Contribution to journalArticle

Beigi, Richard H. ; Bunge, Katherine ; Song, Yeohan ; Lee, Bruce. / Epidemiologic and economic effect of methicillin-resistant staphylococcus aureus in obstetrics. In: Obstetrics and Gynecology. 2009 ; Vol. 113, No. 5. pp. 983-991.
@article{d9582ff12b38458f91976414cf58eeca,
title = "Epidemiologic and economic effect of methicillin-resistant staphylococcus aureus in obstetrics",
abstract = "OBJECTIVE: To quantify the epidemiologic and economic burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in the obstetric population, identify main factors influencing the magnitude of disease, and evaluate the cost-effectiveness of MRSA screening and decolonization. METHODS: A cost-effectiveness decision analytic model was constructed for estimations from both the societal and third party-payer perspectives. Probabilities were derived from prior studies when available. Cost data came from the Healthcare Cost and Utilization Project, medication wholesale prices, and the Centers for Medicare & Medicaid Services. Sensitivity analysis was conducted to assess the effect of variables across a range of values. RESULTS: Approximately 14,294 pregnant or postpartum women experience an invasive MRSA infection in the United States annually. The majority of invasive MRSA infections are mastitis (n=8,880). The annual economic effect of MRSA infections is projected to be approximately $8.7 million and approximately $8.0 million from the societal and payer perspectives, respectively. Sensitivity analyses demonstrate that the prevalence of MRSA, incidence of mastitis, and rate of cesarean deliveries were key driving factors for the estimations. CONCLUSION: Methicillin-resistant S aureus is an important emerging pathogen responsible for a modest burden of puerperal infections and associated costs. Universal screening and decolonization efforts do not currently seem to be cost-effective.",
author = "Beigi, {Richard H.} and Katherine Bunge and Yeohan Song and Bruce Lee",
year = "2009",
month = "5",
doi = "10.1097/AOG.0b013e3181a116e4",
language = "English (US)",
volume = "113",
pages = "983--991",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Epidemiologic and economic effect of methicillin-resistant staphylococcus aureus in obstetrics

AU - Beigi, Richard H.

AU - Bunge, Katherine

AU - Song, Yeohan

AU - Lee, Bruce

PY - 2009/5

Y1 - 2009/5

N2 - OBJECTIVE: To quantify the epidemiologic and economic burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in the obstetric population, identify main factors influencing the magnitude of disease, and evaluate the cost-effectiveness of MRSA screening and decolonization. METHODS: A cost-effectiveness decision analytic model was constructed for estimations from both the societal and third party-payer perspectives. Probabilities were derived from prior studies when available. Cost data came from the Healthcare Cost and Utilization Project, medication wholesale prices, and the Centers for Medicare & Medicaid Services. Sensitivity analysis was conducted to assess the effect of variables across a range of values. RESULTS: Approximately 14,294 pregnant or postpartum women experience an invasive MRSA infection in the United States annually. The majority of invasive MRSA infections are mastitis (n=8,880). The annual economic effect of MRSA infections is projected to be approximately $8.7 million and approximately $8.0 million from the societal and payer perspectives, respectively. Sensitivity analyses demonstrate that the prevalence of MRSA, incidence of mastitis, and rate of cesarean deliveries were key driving factors for the estimations. CONCLUSION: Methicillin-resistant S aureus is an important emerging pathogen responsible for a modest burden of puerperal infections and associated costs. Universal screening and decolonization efforts do not currently seem to be cost-effective.

AB - OBJECTIVE: To quantify the epidemiologic and economic burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in the obstetric population, identify main factors influencing the magnitude of disease, and evaluate the cost-effectiveness of MRSA screening and decolonization. METHODS: A cost-effectiveness decision analytic model was constructed for estimations from both the societal and third party-payer perspectives. Probabilities were derived from prior studies when available. Cost data came from the Healthcare Cost and Utilization Project, medication wholesale prices, and the Centers for Medicare & Medicaid Services. Sensitivity analysis was conducted to assess the effect of variables across a range of values. RESULTS: Approximately 14,294 pregnant or postpartum women experience an invasive MRSA infection in the United States annually. The majority of invasive MRSA infections are mastitis (n=8,880). The annual economic effect of MRSA infections is projected to be approximately $8.7 million and approximately $8.0 million from the societal and payer perspectives, respectively. Sensitivity analyses demonstrate that the prevalence of MRSA, incidence of mastitis, and rate of cesarean deliveries were key driving factors for the estimations. CONCLUSION: Methicillin-resistant S aureus is an important emerging pathogen responsible for a modest burden of puerperal infections and associated costs. Universal screening and decolonization efforts do not currently seem to be cost-effective.

UR - http://www.scopus.com/inward/record.url?scp=66149117462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149117462&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e3181a116e4

DO - 10.1097/AOG.0b013e3181a116e4

M3 - Article

VL - 113

SP - 983

EP - 991

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 5

ER -